Aileen Chang, OD
Optometry · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chang’s office at (408) 524-5900 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$61,669
Medicare paid this office $61,669 for 439 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 170 | $17,538 | $101 |
| Short return visit (20+ min) | 136 | $11,622 | $73 |
| Return visit (30+ min) | 58 | $5,822 | $97 |
| Exam of visual field with extended testing | 73 | $4,941 | $54 |
| New patient complete exam of visual system | 34 | $4,093 | $120 |
See all 11 services
| Established patient complete exam of visual system | 170 | $17,538 | $101 |
| Short return visit (20+ min) | 136 | $11,622 | $73 |
| Return visit (30+ min) | 58 | $5,822 | $97 |
| Exam of visual field with extended testing | 73 | $4,941 | $54 |
| New patient complete exam of visual system | 34 | $4,093 | $120 |
| Imaging of optic nerve | 125 | $4,090 | $32 |
| New patient visit (45+ min) | 28 | $3,601 | $129 |
| New patient visit (30+ min) | 30 | $2,800 | $93 |
| Imaging of retina | 17 | $571 | $34 |
| Imaging of retina with remote review by physician | 26 | $351 | $13 |
| Ultrasound scan of cornea to determine thickness | 19 | $180 | $9 |
Who their Medicare patients are
439 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 11% · Women 58% · Also on Medicaid 12% · Health risk score 0.87. At or below the middle of the specialty; the typical optometry clinician is at 0.97.
Conditions among them: High blood pressure 64% · Diabetes 42% · Chronic kidney disease 25% · Coronary heart disease 20% · Cancer 13% · Atrial fibrillation 11% · Depression 11% · Heart failure 8% · COPD 5% · Stroke 5%.
The office billed $272,982, Medicare allowed $93,749 and paid $61,669; for 1,087 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 439 | 1,087 | 75 | 0.87 | $272,982 | $61,669 |
| 2023 | 371 | 735 | 76 | 0.92 | $235,785 | $54,928 |
| 2022 | 436 | 783 | 76 | 0.86 | $247,867 | $62,492 |
| 2021 | 309 | 496 | 75 | 0.84 | $163,588 | $44,313 |
| 2020 | 325 | 512 | 75 | 1.02 | $167,711 | $44,263 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Established patient complete exam of visual system | 203 | $21,760 | $106 |
| Short return visit (20+ min) | 115 | $11,932 | $76 |
| Exam of visual field with extended testing | 73 | $5,422 | $60 |
| Imaging of optic nerve | 124 | $4,045 | $32 |
| Return visit (30+ min) | 30 | $3,221 | $104 |
| New patient complete exam of visual system | 30 | $3,129 | $104 |
| New patient visit (45+ min) | 16 | $2,059 | $129 |
| New patient visit (30+ min) | 21 | $1,851 | $88 |
| Imaging of retina | 19 | $780 | $41 |
| Ultrasound scan of cornea to determine thickness | 21 | $202 | $9 |
2022: 11 services
| Established patient complete exam of visual system | 163 | $17,326 | $106 |
| Short return visit (20+ min) | 137 | $14,084 | $81 |
| New patient complete exam of visual system | 79 | $9,602 | $122 |
| Exam of visual field with extended testing | 83 | $5,746 | $62 |
| New patient visit (30+ min) | 44 | $3,852 | $88 |
| Return visit (30+ min) | 31 | $3,750 | $121 |
| Imaging of optic nerve | 104 | $3,459 | $33 |
| New patient visit (45+ min) | 20 | $2,454 | $123 |
| Imaging of retina | 19 | $739 | $39 |
| Exam of the internal drainage system of eye | 13 | $337 | $26 |
| Ultrasound scan of cornea to determine thickness | 26 | $266 | $10 |
2021: 10 services
| Established patient complete exam of visual system | 108 | $12,898 | $119 |
| New patient complete exam of visual system | 60 | $8,257 | $138 |
| Short return visit (20+ min) | 58 | $6,512 | $87 |
| Return visit (30+ min) | 31 | $3,424 | $107 |
| New patient visit (45+ min) | 28 | $3,198 | $114 |
| New patient visit (30+ min) | 30 | $2,892 | $96 |
| Imaging of optic nerve | 70 | $2,515 | $36 |
| Exam of visual field with extended testing | 32 | $2,035 | $62 |
| Photography of the retina | 13 | $451 | $35 |
| Ultrasound scan of cornea to determine thickness | 19 | $203 | $11 |
2020: 11 services
| New patient visit (45+ min) | 76 | $10,679 | $141 |
| New patient complete exam of visual system | 59 | $7,543 | $128 |
| Return visit (30+ min) | 78 | $7,407 | $93 |
| Established patient complete exam of visual system | 57 | $6,045 | $106 |
| Short return visit (20+ min) | 42 | $3,638 | $69 |
| Imaging of optic nerve | 66 | $2,468 | $37 |
| Exam of visual field with extended testing | 34 | $2,431 | $64 |
| New patient visit (30+ min) | 25 | $2,036 | $81 |
| Photography of the retina | 12 | $519 | $43 |
| Imaging of retina | 11 | $452 | $41 |
| Ultrasound scan of cornea to determine thickness | 20 | $220 | $11 |
Drugs they prescribed that Part D paid
$66,290
Pharmacies billed $66,290 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 471) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
164 generic and 307 brand-name prescriptions · $66,290 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 18 | $21,288 | $1,183 |
| Lumigan | 40 | $17,554 | $439 |
| Latanoprost | 247 | $3,332 | $13 |
| Timolol Maleate | 42 | $296 | $7 |
| Dorzolamide | 19 | $265 | $14 |
See all 7 drugs
| Restasis | 18 | $21,288 | $1,183 |
| Lumigan | 40 | $17,554 | $439 |
| Latanoprost | 247 | $3,332 | $13 |
| Timolol Maleate | 42 | $296 | $7 |
| Dorzolamide | 19 | $265 | $14 |
| Dorzolamide-Timolol | 17 | $167 | $10 |
| Erythromycin | 13 | $100 | $8 |
Year by year
| 2024 | 471 | 120 | 0% (0) | 65% | $66,290 |
| 2023 | 438 | 105 | 0% (0) | 61% | $80,171 |
| 2022 | 191 | 69 | 0% (0) | 54% | $21,122 |
| 2021 | 92 | 41 | 0% (0) | 43% | $9,319 |
| 2020 | 173 | 92 | 0% (0) | 42% | $31,215 |
| 2019 | 1,084 | 276 | 0% (0) | 61% | $272,310 |
| 2018 | 320 | 129 | 0% (0) | 67% | $65,648 |
| 2014 | 180 | 43 | 0% (0) | 67% | $21,579 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Restasis | 26 | $28,414 | $1,093 |
| Lumigan | 40 | $17,324 | $433 |
| Rhopressa | 12 | $4,012 | $334 |
| Travoprost | 12 | $3,835 | $320 |
| Latanoprost | 202 | $3,791 | $19 |
| Vyzulta | 13 | $3,300 | $254 |
| Brimonidine | 14 | $1,906 | $136 |
| Dorzolamide | 11 | $412 | $37 |
| Dorzolamide-Timolol | 23 | $202 | $9 |
| Timolol Maleate | 21 | $200 | $10 |
| Erythromycin | 12 | $107 | $9 |
2022: 6 drugs
| Lumigan | 16 | $4,902 | $306 |
| Rhopressa | 11 | $3,499 | $318 |
| Latanoprost | 72 | $1,612 | $22 |
| Erythromycin | 22 | $249 | $11 |
| Timolol Maleate | 13 | $132 | $10 |
| Brimonidine | 14 | $93 | $7 |
2021: 2 drugs
| Latanoprost | 28 | $478 | $17 |
| Erythromycin | 21 | $262 | $12 |
2020: 4 drugs
| Restasis | 29 | $22,197 | $765 |
| Olopatadine | 26 | $1,732 | $67 |
| Latanoprost | 34 | $704 | $21 |
| Erythromycin | 39 | $456 | $12 |
2019: 19 drugs
| Restasis | 233 | $169,257 | $726 |
| Travatan Z | 70 | $13,890 | $198 |
| Lotemax | 58 | $12,420 | $214 |
| Alphagan P | 47 | $11,646 | $248 |
| Pazeo | 55 | $10,768 | $196 |
| Olopatadine | 145 | $9,077 | $63 |
| Xiidra | 12 | $6,432 | $536 |
| Prolensa | 17 | $4,507 | $265 |
| Lumigan | 18 | $4,159 | $231 |
| Combigan | 12 | $2,870 | $239 |
| Azelastine | 72 | $2,375 | $33 |
| Prednisolone Acetate | 42 | $2,189 | $52 |
| Latanoprost | 104 | $1,319 | $13 |
| Timolol Maleate | 19 | $976 | $51 |
| Tobramycin-Dexamethasone | 11 | $871 | $79 |
| Dorzolamide-Timolol | 13 | $451 | $35 |
| Erythromycin | 22 | $262 | $12 |
| Diclofenac | 17 | $258 | $15 |
| Tobramycin | 25 | $236 | $9 |
2018: 10 drugs
| Restasis | 58 | $37,208 | $642 |
| Travatan Z | 18 | $4,085 | $227 |
| Lotemax | 18 | $3,514 | $195 |
| Alphagan P | 15 | $3,386 | $226 |
| Pazeo | 14 | $2,559 | $183 |
| Prednisolone Acetate | 42 | $2,326 | $55 |
| Olopatadine | 26 | $1,366 | $53 |
| Azelastine | 13 | $484 | $37 |
| Latanoprost | 23 | $311 | $14 |
| Tobramycin | 14 | $155 | $11 |
2014: 4 drugs
| Lumigan | 29 | $3,726 | $128 |
| Patanol | 23 | $3,638 | $158 |
| Combigan | 14 | $1,472 | $105 |
| Latanoprost | 41 | $522 | $13 |
Money from drug and device companies
$594 in 2025
| 2025 | 5 | 13 | None | $594 |
| 2024 | 3 | 4 | None | $532 |
| 2023 | 1 | 1 | None | $17 |
| 2020 | 3 | 4 | None | $79 |
| 2019 | 10 | 30 | None | $996 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tarsus Pharmaceuticals | Xdemvy | $366 | 7 payments
|
| Bausch & Lomb Americas | Miebo | $145 | 3 payments
|
| Abbvie | Lumigan | $33 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $26 | 1 payment
|
| Alcon Vision | Tryptyr | $24 | 1 payment
|
See all 13 published payments
| Tarsus Pharmaceuticals | Meals · 2025-12-09 | Xdemvy | $10 |
| Tarsus Pharmaceuticals | Meals · 2025-12-02 | None | $14 |
| Tarsus Pharmaceuticals | Meals · 2025-11-06 | None | $146 |
| Tarsus Pharmaceuticals | Meals · 2025-10-28 | Xdemvy | $5 |
| Alcon Vision | Meals · 2025-10-21 | Tryptyr | $24 |
| Oyster Point Pharma | Meals · 2025-10-14 | Tyrvaya | $26 |
| Tarsus Pharmaceuticals | Meals · 2025-10-08 | Xdemvy | $36 |
| Bausch & Lomb Americas | Meals · 2025-10-08 | Miebo | $122 |
| Abbvie | Meals · 2025-08-26 | Lumigan | $33 |
| Bausch & Lomb Americas | Meals · 2025-06-26 | Miebo | $16 |
| Tarsus Pharmaceuticals | Meals · 2025-05-20 | None | $146 |
| Bausch & Lomb Americas | Meals · 2025-04-14 | Vyzulta | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-03-12 | Xdemvy | $10 |
See earlier years (2024, 2023, 2020, 2019)
2024: $532
| Tarsus Pharmaceuticals | Xdemvy | $272 | 2 payments
|
| Bausch & Lomb Americas | Miebo | $134 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $125 | 1 payment
|
2023: $17
| Alcon Vision | Rocklatan | $17 | 1 payment
|
2020: $79
| Carl Zeiss Meditec AG | None Specified | $39 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $21 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Prolensa | $19 | 1 payment
|
2019: $996
| Bausch & Lomb a division of Bausch Health US | Ultra | $215 | 7 payments
|
| Novartis Pharmaceuticals | Xiidra | $210 | 5 payments
|
| Johnson & Johnson Vision Care | Acuvue | $125 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $125 | 1 payment
|
| Sun Pharmaceutical Industries | Bromsite | $111 | 9 payments
|
| Visioneering Technologies | None | $88 | 1 payment
|
| Shire North American Group | Xiidra | $59 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $25 | 1 payment
|
| Alimera Sciences | Iluvien | $19 | 1 payment
|
| Eyevance Pharmaceuticals | Flarex | $18 | 1 payment
|
Professional record
- NPI
- 1356781785
- Licence
- CA 14626TLG, NY TUV007978
- Trained
- Southern California College of Optometry, 2013
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2013-06-30
- NPI last updated
- 2020-02-19
- NPI record certified
- 2020-02-19
This is when the NPI record was last certified, not a medical board exam.